查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571808

老龄化相关性黄斑部病变市场规模、份额、趋势分析报告：按产品、疾病、分销管道、地区、细分市场预测，2024-2030

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis), By Disease (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

老龄化黄斑部病变市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计到2030年，全球老龄化黄斑部病变市场规模将达到179.9亿美元，2024年至2030年复合年增长率为8.2%。

这一增长归因于新产品开发、产品发布的高研发投资、老龄化黄斑部病变(AMD) 盛行率的上升以及老年人口的不断增长。

尚未核准治疗干老龄化黄斑部病变的药物。这为市场相关人员提供了解决干性 AMD 患者未满足的医疗需求的机会。然而，对于湿型AMD ，可以使用抗VEGF药物来治疗和防止疾病进一步恶化。

由于经常去医院和短时间给药，患者往往在没有完成治疗的情况下停止治疗。为了满足此类产品日益增长的需求，各大公司正在研究开发长效抗VEGF产品。 2020 年 2 月，诺华公司的 Beovu 获得了欧盟委员会的核准，这是一种治疗老龄化黄斑部病变的药物。该药物是一种长效药物，第一年每 12 週给药一次。

此外，罗氏公司的老龄化黄斑部病变治疗药物Babismo（faricimab）是一种负荷剂量製剂，注射週期为4週，于2022年1月获得美国FDA批准用于治疗核准作为老龄化相关性黄斑部病变的治疗药物。此外，2021年10月，罗氏的Susvimo获得FDA核准，预计2022年在美国上市。这是一款专为 LUCENTIS 给药而设计的可再填充植入，可再填充期为 6 个月。所有这些因素预计将在预测期内推动市场成长。

EYLEA 的专利到期年份在美国为 2023 年，在欧洲为 2025 年，取决于多个专利类别。 Lucentis（F. Hoffmann La Roche Ltd.）于 2020 年 6 月在美国失去专利，并于 2022 年在欧洲失去专利。因此，生物相似药製造商正在寻找进入 AMD 市场的机会。例如，2021 年 10 月，Formycon AG 和 Bioeq AG 的Lucentis生物相似药获得了美国FDA 的 BLA 认可。 PDUFA 审核申请的日期定于 2022 年 8 月。所有这些因素都可能会阻碍预测期内的市场成长。

老龄化黄斑部病变市场报告亮点

  • 2023 年，Eylea 细分市场的最大市场占有率为 47.7%。市场成长是由专利保护和高市场渗透率推动的。 Eylea 用于治疗损害视网膜或黄斑部、导致视力问题的眼科疾病。
  • 医院药房细分市场占据主导地位，并在 2023 年占据最大份额。这种主导地位是由于老龄化黄斑部病变（AMD）盛行率和住院治疗的不断上升。
  • 湿型AMD细分市场在 2023 年占据最大市场占有率。老年人口的增加是影响细分市场成长的主要因素之一。据 Genentech 称，北美每年确认约 20 万例新湿型AMD病例。
  • 北美老龄化黄斑部病变市场在 2023 年占据主导地位。根据美国眼科学会的数据，大约 150 万美国患有威胁视力的晚期 AMD，1,830 万美国患有早期 AMD。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章老龄化黄斑部病变市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 老龄化黄斑部病变市场分析工具
    • 波特的分析
    • PESTEL分析

第四章老龄化黄斑部病变市场：产品估算与趋势分析

  • 细分仪表板
  • 老龄化黄斑部病变市场：产品变化分析，百万美元，2023 年和 2030 年
  • Eylea
  • Lucentis
  • Beovu
  • 其他的

第五章老龄化黄斑部病变市场：疾病估计与趋势分析

  • 细分仪表板
  • 老龄化黄斑部病变市场：疾病变化分析，百万美元，2023 年和 2030 年
  • 湿型AMD
  • 干性AMD

第六章老龄化黄斑部病变市场：通路估算及趋势分析

  • 细分仪表板
  • 老龄化黄斑部病变市场：分销管道波动分析，百万美元，2023 年和 2030 年
  • 医院药房
  • 专业药房
  • 网路药房

第七章老龄化黄斑部病变市场：区域估计及趋势分析

  • 2023 年和 2030 年老龄化黄斑部病变市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第八章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Regeneron Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen
    • Samsung Bioepis
简介目录
Product Code: GVR-4-68039-971-3

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, registering to grow at a CAGR of 8.2% from 2024 to 2030 according to a new report by Grand View Research, Inc. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

  • The Eylea segment accounted for the largest market share of 47.7% in 2023. The market growth is attributed to patent protection and high market penetration. Eylea is prescribed for eye conditions that harm the retina or macula leading to impaired vision.
  • The hospital pharmacy segment dominated the market and accounted for the largest share in 2023. This dominance can be attributed to the rise in the prevalence of age-related macular degeneration (AMD) and hospitalization for treatment.
  • The wet AMD segment accounted for the largest market share in 2023. The growing geriatric population is one of the major factors influencing segment growth. According to Genentech, approximately 200,000 new instances of wet AMD are identified annually in North America.
  • North America age-related macular degeneration market dominated the market in 2023. According to the American Academy of Ophthalmology, approximately 1.5 million Americans have late AMD, which is the vision-threatening type of AMD and 18.3 million Americans are affected by early AMD.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Age-Related Macular Degeneration Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Age-Related Macular Degeneration Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Age-Related Macular Degeneration Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Age-Related Macular Degeneration Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Eylea
    • 4.3.1. Eylea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lucentis
    • 4.4.1. Lucentis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beovu
    • 4.5.1. Beovu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Age-Related Macular Degeneration Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Age-Related Macular Degeneration Market: Disease Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Wet AMD
    • 5.3.1. Wet AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Dry AMD
    • 5.4.1. Dry AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Age-Related Macular Degeneration Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Age-Related Macular Degeneration Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Specialty Pharmacy
    • 6.4.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Age-Related Macular Degeneration Market: Regional Estimates & Trend Analysis

  • 7.1. Age-Related Macular Degeneration Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Bayer AG
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bausch Health Companies Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Regeneron Pharmaceuticals Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Amgen Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Biogen
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Samsung Bioepis
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives